Unlock instant, AI-driven research and patent intelligence for your innovation.

Treatment of urinary dysfunction

A benign, detrusor technology, applied in urinary system diseases, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as small up-regulation

Inactive Publication Date: 2008-04-23
INTREAT AB
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] It is believed that fast type P2X 7 Also works with P2X 4 and P2X 6 Up-regulated together, but to a lesser extent

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The urodynamics of 18 female DI patients aged 30-81 were tested. These tests showed that an average of 173 mL (range 50-350 mL) required urgent emptying. The mean maximum bladder capacity was 340 mL (range 150-570 mL). Mean maximum detrusor pressure of 48 cm H 2 O (range is 18-100cm H2O).

[0036] with P2X 3 or P2X 5 Microscopic examination of parasympathetic varicosities where one of the subtype receptors co-localized did not reveal any SV2-labeled neurotransmitter release sites. Synthesis or expression of these two isoforms was significantly reduced in the detrusor muscle of DI patients compared with 22 adult control bladders.

[0037] In unstable muscles of DI patients compared with controls, P2X 4 and P2X 5 Subtypes were more associated with SV2-pigmented varicose veins (36% and 33% vs. 16% and 18%, respectively), but similar to controls, contrast analysis showed that the above subtypes showed more Cy2 fluorescence than P2X 1 and P2X 2 Be low (7 Immunolocal...

Embodiment 2

[0040] The animals used in the study were rats fed for 6 months on a phytoestrogen-free diet or on the same diet supplemented with safflower (5%) as a typical phytoestrogen-enriched diet. The bladders of rats fed a phytoestrogen-free diet were not significantly different from normal bladders in terms of P2X receptor expression. Whereas for rats fed with the safflower supplement, it was clear that P2X 1 , P2X 2 , P2X 3 and P2X 5 Reduced expression, concomitant P2X at subsynaptic sites 4 and P2X 6 Increase.

[0041] Treatment: For male or female patients with DI and SU, the dosage of Promesil is 40-160mg / day, and the dose is adjusted according to the patient's response to relieve the symptoms of urinary incontinence.

Embodiment 3

[0043] Treatment: For male patients with benign prostatic hyperplasia affecting self-control, the dose of Promensil is 40mg / day.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treatment or prevention of urinary dysfunction in a mammal. The composition includes a pharmaceutically effective amount of one or more substances capable of enabling the bladder of the mammal to mimic conditions found in advanced pregnancy. Alternately, the pharmaceutical composition has a pharmaceutically effective amount of one or more substances adapted to regulate the expression of one or more ATPases that control the supply of ATP to P2X receptors in the bladder of the mammal. In one aspect, the pharmaceutical composition may downregulate expression of subtype receptors P2X1, P2X2, P2X3 and P2X5, possibly upregulating expression of subtype receptors P2X4 and P2X6.

Description

[0001] This application is a divisional application filed on August 28, 2001 with the application number 01814824.7 and the title of the invention being "treatment of urinary insufficiency". technical field [0002] The present invention relates to the prevention and / or treatment of continence problems, including treatment of urinary incontinence caused by benign prostatic hyperplasia in male animals, detrusor instability or urinary urgency in both female and male animals. Specifically, the present invention can be used to treat the intractable diseases described above; however, the present invention is not necessarily limited to the treatment of the intractable diseases described above. [0003] The present invention particularly relates to the treatment of human incontinence, but again is not limited thereto. Background technique [0004] Urinary incontinence is recognized as a problem with social and economic implications for both men and women. Both sexes can suffer fro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/57A61K31/352A61P13/08A61P13/10A61K45/00A61P13/02
CPCA61K31/57A61K31/352A61P13/02A61P13/08A61P13/10A61P31/10
Inventor J·A·巴尔丹A·基得利-拜尔德
Owner INTREAT AB